In our HT-29 colorectal carcinoma model, KAE reduced GM-CSF expression by nearly 50%, closely matching the effect of cisplatin, and effectively limiting pro-tumor myeloid populations and inflammation-driven proliferation. This evidence concerns the gene CSF2 and colorectal carcinoma.